1.	Efficacy of G-CSF-Priming in Elderly AML Patients Phase: Phase IV Type: Treatment Status: Active Age: Over 60 Sponsor: Other Protocol IDs: AML-elderly 01/99 Trial, NCT00199147
2.	Allogeneic Transplantation for Pediatric Leukemias With Unrelated Donors Phase: Phase IV Type: Treatment Status: Active Age: 21 and under Sponsor: Other Protocol IDs: SCT 0208, NCT00679536
3.	Busulfan and Cyclophosphamide Instead of Total Boby Irradiation (TBI) and Cyclophosphamide for Hematological Malignancies Hematocrit (HCT) Phase: Phase IV Type: Treatment Status: Approved-not yet active Age: 21 and under Sponsor: Other Protocol IDs: TASMC-11-MB-442-CTIL, NCT01339988
4.	Microtransplantation With Decitabine and Cytarabine Improves Patient Outcomes in Myelodysplastic Syndromes Phase: Phase IV Type: Treatment Status: Active Age: 10 to 90 Sponsor: Other Protocol IDs: MST/MDS-307PLAH-ASH, NCT01674985
5.	Combination Chemotherapy With or Without Gemtuzumab Ozogamicin or Tipifarnib in Treating Patients With Acute Myeloid Leukemia or High-Risk Myelodysplastic Syndromes. Note: The information about this trial has not been updated by the sponsor/principal investigator/lead organization. Cancer.gov cannot verify the accuracy of the information. Phase: Phase III, Phase II Type: Biomarker/Laboratory analysis, Treatment Status: Active Age: Any age Sponsor: Other Protocol IDs: UHW-AML16, EU-20677, ISRCTN11036523, EUDRACT-2005-002846-14, MREC-CU106, NCT00454480
6.	Low-energy Laser Therapy for Prevention of Oral Mucositis in Children Phase: Phase III, Phase II Type: Supportive care, Treatment Status: Active Age: 0 to 18 Sponsor: Other Protocol IDs: CHU-0060, NCT01007617
7.	Efficacy Study of CHG Regimen vs Decitabine to Treat Higher-risk MDS Phase: Phase III, Phase II Type: Treatment Status: Approved-not yet active Age: 16 to 80 Sponsor: Other Protocol IDs: CHG-DAC 001, SHDC12010202, NCT01417767
8.	Stem Cell Transplant for Hematological Malignancy Phase: Phase III Type: Treatment Status: Active Age: 54 and under Sponsor: Other Protocol IDs: 0107M05202, MT2001-02, NCT00176930
9.	Sibling Donor Peripheral Stem Cell Transplant or Sibling Donor Bone Marrow Transplant in Treating Patients With Hematologic Cancers or Other Diseases. Note: The information about this trial has not been updated by the sponsor/principal investigator/lead organization. Cancer.gov cannot verify the accuracy of the information. Phase: Phase III Type: Treatment Status: Active Age: 16 to 65 Sponsor: NCI Protocol IDs: CBMTG-0601, NCT00438958
10.	A Remission Induction Therapy and Risk-oriented Postremission Strategy for Adult Acute Myelogenous Leukemia (AML) Phase: Phase III Type: Treatment Status: Active Age: 16 to 65 Sponsor: Other Protocol IDs: NILG-AML 02/06, NCT00495287
11.	Myeloablative Hematopoietic Progenitor Cell Transplantation (HPCT) for Pediatric Malignancies Phase: Phase III Type: Treatment Status: Active Age: 21 and under Sponsor: Other Protocol IDs: SCT 0307, NCT00619879
12.	Dose-Reduced Versus Standard Conditioning Prior Allo SCT for MDS/sAML Patients Phase: Phase III Type: Treatment Status: Active Age: 18 to 65 Sponsor: Other Protocol IDs: RICMAC, EBMT 42205525, NCT00682396
13.	Randomized Allogeneic Azacitidine Study Phase: Phase III Type: Treatment Status: Active Age: 18 to 75 Sponsor: Other Protocol IDs: 2008-0503, NCT00887068
14.	A Study of Lenalidomide Versus Placebo in Subjects With Transfusion Dependent Anemia in Low Risk Myelodysplastic Syndrome (MDS) Without Del 5Q Phase: Phase III Type: Health services research, Supportive care, Treatment Status: Active Age: 18 and over Sponsor: Pharmaceutical / Industry Protocol IDs: CC-5013-MDS-005, NCT01029262
15.	Comparison Study of Standard Care Against Combination of Growth Factors Agents for Low-risk Myelodysplastic Syndromes Phase: Phase III Type: Treatment Status: Approved-not yet active Age: 18 and over Sponsor: Other Protocol IDs: MDS201001, 2009-017462-23, CRUK/08/009, NCT01196715
16.	Graft-Versus-Host Disease Prophylaxis in Treating Patients With Hematologic Malignancies Undergoing Unrelated Donor Peripheral Blood Stem Cell Transplant Phase: Phase III Type: Biomarker/Laboratory analysis, Supportive care, Treatment Status: Active Age: not specified Sponsor: NCI, Other Protocol IDs: 2448.00, NCI-2010-02035, P01CA018029, NCT01231412
17.	Randomized Study of ON 01910.Na in Refractory Myelodysplastic Syndrome Patients With Excess Blasts Phase: Phase III Type: Treatment Status: Active Age: 18 and over Sponsor: Pharmaceutical / Industry Protocol IDs: 04-21, NCT01241500
18.	Study of REVLIMID (Lenalidomide) Versus Placebo in Patients With Low Risk Myelodysplastic Syndrome Phase: Phase III Type: Treatment Status: Active Age: 18 and over Sponsor: Other Protocol IDs: SINTRA-REV, 2009-013619-36, NCT01243476
19.	Comparison of Cy-Atg Versus Flu-Atg for the Conditioning Therapy in Allogeneic Hematopoietic Cell Transplantation (Allo-HCT) for Bone Marrow Failure Syndrome Phase: Phase III Type: Treatment Status: Active Age: 15 to 65 Sponsor: Other Protocol IDs: C-021, NCT01145976
20.	Reduced Intensity Conditioning Versus Myeloablative Conditioning for Acute Myeloid Leukemia or Myelodysplastic Syndrome (BMT CTN 0901) Phase: Phase III Type: Treatment Status: Active Age: 18 to 65 Sponsor: NCI, Other Protocol IDs: 709, U01HL069294, U01HL069294-05, 0901, NCT01339910
21.	PRO#1278: Fludarabine and Busulfan vs. Fludarabine, Busulfan and Total Body Irradiation Phase: Phase III Type: Treatment Status: Active Age: 18 to 70 Sponsor: Other Protocol IDs: PRO#1278: Flu-Bu-TBI, NCT01366612
22.	An Efficacy Study for Epoetin Alfa in Anemic Patients With Myelodysplastic Syndromes Phase: Phase III Type: Treatment Status: Active Age: 18 and over Sponsor: Pharmaceutical / Industry Protocol IDs: CR018367, EPOANE3021, 2010-022884-36, NCT01381809
23.	Fludarabine-IV Busulfan ± Clofarabine and Allogeneic Hematopoietic Stem Cell Transplantation for Acute Myeloid Leukemia (AML) and Myelodysplastic Syndrome (MDS) Phase: Phase III Type: Treatment Status: Active Age: 3 to 70 Sponsor: Other Protocol IDs: 2011-0628, NCT01471444
24.	Study Comparing G-CSF Mobilized Peripheral Blood and G-CSF Stimulated Bone Marrow in Patients Undergoing Matched Sibling Transplantation Phase: Phase III Type: Treatment Status: Active Age: 16 to 65 Sponsor: Other Protocol IDs: 2081-076, NCT01530581
25.	Italian Platelet Technology Assessment Study Phase: Phase III Type: Supportive care, Treatment Status: Active Age: 18 and over Sponsor: Other Protocol IDs: ISS-2007646931, NCT01642563